Blasts of a Different Sort
Can you tell what the diagnosis is for a man with a history of recurrent necrotizing pancreatitis and end-stage renal disease on intermittent hemodialysis by looking at his
Combining Daratumumab With Backbone Antimyeloma Agents
Dr. Raje reviews a study that compares daratumumab, lenalidomide, and dexamethasone with lenalidomide and dexamethasone alone for the treatment of patients with multiple my
Dr. DeBaun covers updates from 2016 in the treatment of SCD and discusses the potential availability of a new therapy for preventing vaso-occlusive pain episodes.
Dr. Garcia looks at the best of 2016 in the field of platelet disorders.
Dr. Moss covers updates in the management of the most common subtype of leukemia (CLL), focusing on the value of BTK inhibition.
November/December 2016 Volume 13, Issue 6
View all Features articles
View all Diffusion articles
Dr. Charles Abrams talks about the Society's accomplishments during 2016 and initiatives on the horizon made possible by ASH members.
View all president's column articles
View all Ask the Hematologist articles
View all Op-Ed articles
View all Mini Review articles
Through a notice on its website, the Drug Enforcement Administration (DEA) recently announced significant changes to its registration renewal process. Effective January 1, 2017, the DEA is eliminating the informal grace period which the agency has previously allowed for registrants to renew their registrations.
On December 15, 2016, the Centers for Medicare and Medicaid Services (CMS) announced the cancellation of Medicare Part B Drug Payment Model. CMS initially proposed the demonstration on March 8, 2016 to test new models in how physician-administered drugs are paid under the Medicare program.
ASH is pleased to see the National Heart, Lung and Blood Institute’s (NHLBI) continuous support (RFA-HL-15-030) for the development of improved techniques to enhance the production of clinically relevant, functional stem cell-derived red blood cells or platelets.
The American Society of Hematology (ASH) is committed to addressing the burden of sickle cell disease (SCD) and is undertaking a multifaceted initiative to improve outcomes for individuals with
the disease, both in the United States and globally.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology